Bioseeker, Feb 2011
) suspended drugs and the accumulated number of ceased drugs over the last years amount to another 165 (155) drugs. BreastCancerDrugPipelineUpdate lists all drugs and gives you a progress analysis on each
Bioseeker, Feb 2011
in a Highly Competitive Market Place
BreastCancerDrugPipelineUpdate 2011-.
The Package Includes
- A progress analysis on current and emerging drugs
- Information on most companies active in breastcancer
La Merie, July 2010, Pages: 49
become the mainstay in the treatment of Her2-positive breastcancer. Combining trastuzumab with the potent cytotoxic DM1 via a stable linker resulted in the antibody-drug conjugate (ADC) trastuzumab-DM1
BioPharm Reports (VennBio Ltd.), Jan 2011, Pages: 124
, based on new and established classes. This 2011 report gives a comprehensive update on current therapeutic and diagnostic development in this field, on the drug development pipeline and the most promising
Life Science Analytics, March 2011, Pages: 1452
BreastCancer Therapy Area Pipeline Report contains detailed information on the breastcancerdrugpipeline. This report provides insight into the pipeline status of breastcancerdrugs by company
Espicom Business Intelligence Ltd, May 2011
savings.
CANCER ANALYSIS PROVIDES:
- Company Performance, Products and Research Pipelines:
Regularly updated and detailed analysis of over 120 leading companies' strategy, research, products
Bioseeker, Feb 2011
- Where to Commercialize?
Protein Kinase Inhibitors in Oncology: DrugPipelineUpdate 2011-
The Package Includes
- A progress analysis on current and emerging drugs
- Information on most companies active
Global Markets Direct, Dec 2010, Pages: 38
of action, therapeutic class, target and major milestones.
- Recent updates of the Austrian Breast & Colorectal Cancer Group’s pipeline in the last quarter.
- Key discontinued and dormant projects
La Merie, Jan 2010, Pages: 19
representative of these drugs and has been introduced in treatment advanced breastcancer, in the neoadjuvant and adjuvant setting and for prevention of the disease. Other compounds are in development for breast
Bioseeker, Dec 2007, Pages: 430
by Molecular Function Classes of Targets 3(3)
Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets
Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target
Global Markets Direct, March 2011, Pages: 66
BreastCancer Study Group.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination
GlobalData, Dec 2010, Pages: 64
to the products.
Reasons to buy
- Identify new drug targets and therapeutic classes in International BreastCancer Study Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those
Global Industry Analysts, Inc., Feb 2011, Pages: 682
Breakdown Based on Relative
Oncology Application (includes corresponding Graph/Chart) 22
Cilengitide 23
Imiquimod 23
Angiogenesis Inhibitors - Pipeline Status 24
Select Anti-Angiogenesis Drugs in Phase
Global Markets Direct, Dec 2010, Pages: 64
BreastCancer Study Group.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination
Global Markets Direct, Dec 2010, Pages: 35
’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Kimmel Cancer Center in its therapy areas of focus.
- Identify new drug targets
Global Markets Direct, Jan 2011, Pages: 213
therapeutic pipeline. This report provides information on the therapeutic development for Metastatic BreastCancer, complete with latest updates, and special features on late-stage and discontinued projects
Datamonitor, April 2010, Pages: 243
of the current small molecule targeted cancer therapies pipeline by developmental phase, drug target and company
-Insight and analysis of market potential including commercial opportunity and discussion of unmet
Global Markets Direct, Jan 2012, Pages: 353
therapeutic pipeline. This report provides information on the therapeutic development for Metastatic BreastCancer, complete with latest updates, and special features on late-stage and discontinued projects
